Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions

by Christopher J Lord, Niall Quinn, Colm J Ryan
Published 2020-05-01

NLK is a novel therapeutic target for PTEN deficient tumour cells.

by Ana M Mendes-Pereira, Christopher J Lord, Alan Ashworth
Published 2012-01-01

A Machine-Learning Tool Concurrently Models Single Omics and Phenome Data for Functional Subtyping and Personalized Cancer Medicine

by Gift Nyamundanda, Katherine Eason, Justin Guinney, Christopher J. Lord, Anguraj Sadanandam
Published 2020-09-01

Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR

by Saira Khalique, Stephen J Pettitt, Ger Kelly, Nina Tunariu, Rachael Natrajan, Susana Banerjee, Christopher J Lord
Published 2020-01-01

Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer

by Agnieszka K. Witkiewicz, Sejin Chung, Rachel Brough, Paris Vail, Jorge Franco, Christopher J. Lord, Erik S. Knudsen
Published 2018-01-01

Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets

by Dragomir B. Krastev, Stephen J. Pettitt, James Campbell, Feifei Song, Barbara E. Tanos, Stoyno S. Stoynov, Alan Ashworth, Christopher J. Lord
Published 2018-05-01

Cross-species identification of PIP5K1-, splicing- and ubiquitin-related pathways as potential targets for RB1-deficient cells.

by Andrey A Parkhitko, Arashdeep Singh, Sharon Hsieh, Yanhui Hu, Richard Binari, Christopher J Lord, Sridhar Hannenhalli, Colm J Ryan, Norbert Perrimon
Published 2021-02-01

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

by Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna Riffell, Alberto Bardelli, Christopher Torrance, Christopher J Lord, Alan Ashworth
Published 2016-01-01

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

by Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna Riffell, Alberto Bardelli, Christopher Torrance, Christopher J Lord, Alan Ashworth
Published 2018-01-01

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

by Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna Riffell, Alberto Bardelli, Christopher Torrance, Christopher J Lord, Alan Ashworth
Published 2017-01-01

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

by Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna Riffell, Alberto Bardelli, Christopher Torrance, Christopher J Lord, Alan Ashworth
Published 2016-01-01

Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer.

by Louise J Barber, Juan M Rosa Rosa, Iwanka Kozarewa, Kerry Fenwick, Ioannis Assiotis, Costas Mitsopoulos, David Sims, Jarle Hakas, Marketa Zvelebil, Christopher J Lord, Alan Ashworth
Published 2011-01-01

A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity.

by Stephen J Pettitt, Farah L Rehman, Ilirjana Bajrami, Rachel Brough, Fredrik Wallberg, Iwanka Kozarewa, Kerry Fenwick, Ioannis Assiotis, Lina Chen, James Campbell, Christopher J Lord, Alan Ashworth
Published 2013-01-01

A modified method for whole exome resequencing from minimal amounts of starting DNA.

by Iwanka Kozarewa, Juan Manuel Rosa-Rosa, Christopher P Wardell, Brian A Walker, Kerry Fenwick, Ioannis Assiotis, Costas Mitsopoulos, Marketa Zvelebil, Gareth J Morgan, Alan Ashworth, Christopher J Lord
Published 2012-01-01

Correction: A Modified Method for Whole Exome Resequencing from Minimal Amounts of Starting DNA

by Iwanka Kozarewa, Juan Manuel Rosa-Rosa, Christopher P. Wardell, Brian A. Walker, Kerry Fenwick, Ioannis Assiotis, Costas Mitsopoulos, Marketa Zvelebil, Gareth J. Morgan, Alan Ashworth, Christopher J. Lord
Published 2012-01-01

Correction: A Modified Method for Whole Exome Resequencing from Minimal Amounts of Starting DNA.

by Iwanka Kozarewa, Juan Manuel Rosa-Rosa, Christopher P. Wardell, Brian A. Walker, Kerry Fenwick, Ioannis Assiotis, Costas Mitsopoulos, Marketa Zvelebil, Gareth J. Morgan, Alan Ashworth, Christopher J. Lord
Published 2012-01-01

Integrated functional, gene expression and genomic analysis for the identification of cancer targets.

by Elizabeth Iorns, Christopher J Lord, Anita Grigoriadis, Sarah McDonald, Kerry Fenwick, Alan Mackay, Charles A Mein, Rachael Natrajan, Kay Savage, Narinder Tamber, Jorge S Reis-Filho, Nicholas C Turner, Alan Ashworth
Published 2009-01-01

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

by Chris T. Williamson, Rowan Miller, Helen N. Pemberton, Samuel E. Jones, James Campbell, Asha Konde, Nicholas Badham, Rumana Rafiq, Rachel Brough, Aditi Gulati, Colm J. Ryan, Jeff Francis, Peter B. Vermulen, Andrew R. Reynolds, Philip M. Reaper, John R. Pollard, Alan Ashworth, Christopher J. Lord
Published 2016-12-01

The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing

by Irene Y. Chong, Naureen Starling, Alistair Rust, John Alexander, Lauren Aronson, Marta Llorca-Cardenosa, Ritika Chauhan, Asif Chaudry, Sacheen Kumar, Kerry Fenwick, Ioannis Assiotis, Nik Matthews, Ruwaida Begum, Andrew Wotherspoon, Monica Terlizzo, David Watkins, Ian Chau, Christopher J. Lord, Syed Haider, Sheela Rao, David Cunningham
Published 2021-01-01

Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma

by Sally L George, Federica Lorenzi, David King, Sabine Hartlieb, James Campbell, Helen Pemberton, Umut H Toprak, Karen Barker, Jennifer Tall, Barbara Martins da Costa, Marlinde L van den Boogaard, M Emmy M Dolman, Jan J Molenaar, Helen E Bryant, Frank Westermann, Christopher J Lord, Louis Chesler
Published 2020-09-01